Compare Natera Inc. Common Stock (NTRA) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Southern Copper Corp — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Southern Copper Corp trades at $197 (market cap $169.44B). The key difference: Southern Copper Corp is far larger — about 3× Natera Inc. Common Stock's market cap, and Southern Copper Corp pays a 2.19% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Southern Copper Corp for 62 Days on average.
| NTRA | SCCO | |
|---|---|---|
Market Cap | $57.03B | $169.44B |
Volume | 1,131,157 | 888,492 |
Sector | Health | Basic Materials |
52-Week High | $425.64 | $219.70 |
52-Week Low | $179.42 | $120.02 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $56.18B | $170.74B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Southern Copper (SCCO) trades at $207.42, down 0.61% on the day, with strong fundamental performance including 35.9% net margins and 50.1% ROE. The stock shows bullish technical signals with support at $207 and resistance at $210, while consistently beating earnings estimates in recent quarters. Revenue growth accelerated to $13.4B in 2025 with net income reaching $4.3B, supported by operational cash flow of $4.8B.
Despite premium valuations (P/E 31.1, P/S 11.2), SCCO's world-class assets and $10.2B Mexican project pipeline support long-term growth. However, analyst consensus remains cautious with only 10% buy ratings and a $165.60 price target, 20% below current levels. Key risks include copper price volatility and the stock's valuation premium relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
